World headquarters in new york. The other big news we are hearing from sources telling bloomberg that President Trump has signed off on that trade deal, phase one with china, and also avoiding that 160 billion of chinese goods being given more tariffs. The plan was for this sunday, the deal could include agricultural goods, purchases from china, not to mention perhaps those existing tariffs also being lifted. Thats get the Market Reaction right away because japan and south korea are coming online. David ingles is in hong kong. What are you seeing . David if you took that and went long in the cash market on sterling or any of these as well, certainly, 13 514 whats your session high on cable. One thing to note on this as 2 wouldthing beyond make this the biggest drop since 2009 so these are quite substantial moves you are seeing. Lets flip the boards and have a look at the open across the region right now. Overall, asia is back to the highest level since august of 2018. I am guessing wit
/PRNewswire/ Laekna Therapeutics announced today that the Center for Drug Evaluation (CDE), the National Medical Products Administration (NMPA) of China has.
Laekna Therapeutics will present two clinical study results in ESMO 2021
News provided by
Share this article
Share this article
SHANGHAI and WARREN, N.J., July 26, 2021 /PRNewswire/ Laekna Therapeutics, an emerging innovative pharma company based in China s Zhangjiang Pharma Valley and New Jersey in the U.S. and focused on developing new groundbreaking innovative therapies to treat cancer and liver diseases, announced today that it will present the results from two clinical studies on the treatment of prostate cancer at the European Society for Medical Oncology (ESMO) Congress 2021.
ePoster
Presentation Number: 597P
This
ClinicalTrials NCT03843918 is a phase I monotherapy dose-escalation study of LAE001, in patients with metastatic castration-resistant prostate cancer (mCRPC). LAE001 is the first CYP17/CYP11B2 dual inhibitor globally. It is a novel, potent, non-steroidal, reversible dual inhibitor of CYP17 and CYP11B2 (aldosterone synthase) that blocks both androgen
Share this article
Share this article
SHANGHAI and GAITHERSBURG, Md., Feb. 24, 2021 /PRNewswire/ I-Mab (the Company ) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March. Details of the conferences and management presentation are as follows:
H.C. Wainwright Global Life Sciences Conference (Virtual)
Presentation: Tuesday, March 9, 2021 at 7:00 a.m. EST
Presenter: Mr. Jielun Zhu, Director and Chief Financial Officer
Webcast link: https://journey.ct.events/view/82bf84ac-4e9c-4ebd-baab-b0bf034e93af. The webcast will also be available under Event Calendar on IMAB s IR website at http://ir.i-mabbiopharma.com/.